Insights

Explore our thought
leadership

Featured

The use of AI in imaging for Alzheimer’s Disease

2023 has already been a landmark year in Alzheimer’s disease (AD) therapeutics: lecanemab (Leqembi), co-developed by Biogen and Eisai, received FDA accelerated approval in January, and Phase 3 results for donanemab (Eli Lilly) are expected in 2Q23, with submission for FDA full approval shortly thereafter (accelerated approval was rejected in January).

Adriana Gonzalez and 2 others

Blogs and publications
by sector

The use of AI in imaging for Alzheimer’s Disease

November 15, 2024 • 2023 has already been a landmark year in Alzheimer’s disease (AD) therapeutics: lecanemab (Leqembi), co-developed by Biogen and Eisai, received FDA accelerated approval in January, and Phase 3 results for donanemab (Eli Lilly) are expected in 2Q23, with submission for FDA full approval shortly thereafter (accelerated approval was rejected in January).

Adriana Gonzalez and 2 others

OSET 2024: The All-in-One Ortho Industry Meeting

October 7, 2024 • 2023 has already been a landmark year in Alzheimer’s disease (AD) therapeutics: lecanemab (Leqembi), co-developed by Biogen and Eisai, received FDA accelerated approval in January, and Phase 3 results for donanemab (Eli Lilly) are expected in 2Q23, with submission for FDA full approval shortly thereafter (accelerated approval was rejected in January).

Masha Dumanis

Blood Biomarkers in Alzheimer’s Disease

September 25, 2024 • 2023 has already been a landmark year in Alzheimer’s disease (AD) therapeutics: lecanemab (Leqembi), co-developed by Biogen and Eisai, received FDA accelerated approval in January, and Phase 3 results for donanemab (Eli Lilly) are expected in 2Q23, with submission for FDA full approval shortly thereafter (accelerated approval was rejected in January).

Juan Valdez-Capuccino and 3 others

Health Equity: The Kx Research Approach and Case Study

April 27, 2023 • Advanced healthcare treatments require patients to pass through multiple specialists or undergo significant surgical procedures.

Evelyn Tee and 2 others

Medtech commercialization, pharma commercialization

Evolving Considerations for Segmenting Aesthetic Practices

April 20, 2023 • The global aesthetics market for product sales has more than doubled in the past 10 years, from $6B to $12.5B. Simultaneously, the number of US aesthetics practices has exploded to exceed 40,000 today.

Bob Serrano and 2 others

Alzheimer’s Disease Therapeutics and Diagnostics – Parallel Advancements for Patient Care

April 20, 2023 • 2023 has already been a landmark year in Alzheimer’s disease (AD) therapeutics: lecanemab (Leqembi), co-developed by Biogen and Eisai, received FDA accelerated approval in January, and Phase 3 results for donanemab (Eli Lilly) are expected in 2Q23, with submission for FDA full approval shortly thereafter (accelerated approval was rejected in January).

Bob Serrano and Brett Larson

Women’s Health: The Opportunity in Gynecology and Beyond

March 8, 2023 • Women’s healthcare and FemTech are garnering increasing attention, yet unmet need remains high, leaving opportunity for investment in an area with significant white space for growth.

Jenna Riffell, PhD and 2 others

Patient Engagement Digital Health Rachael England

For Patient Engagement solutions looking for an exit, 2023 could be their year

February 15, 2023 • After a fraught 2022 that saw a significant slowdown in acquisitions from 2021’s volume and valuation highs, product companies view M&A as a potential strategy in 2023 to enhance their value proposition and achieve efficiencies of scale.

Rachael England

5 Misconceptions for MedTech Market Access Strategy

October 19, 2022 • Market access in MedTech is a complex and rapidly evolving environment, with increasingly intense scrutiny on the costs and benefits of new technologies as the pressure on budgets increases globally.

Jenna Riffell, PhD and Przemek Czerklewicz

Using the Patient Journey to Understand Health Equity Challenges

September 29, 2022 • Unequal healthcare access among different groups leads to less preventative care, and more urgent and intensive procedures. Such disparities in access currently cost the US healthcare system approximately $320 B annually and is projected to grow to as much as $1 trillion annually in 2040.

Evelyn Tee and 2 others

Key Insights & Takeaways: American Association for Clinical Chemistry Annual Scientific Meeting & Clinical Lab Expo

August 23, 2022 • The Clinical Chemistry Annual Meeting did not disappoint with great attendance, engaging talks, and some innovative exhibits. After digesting all our notes (and a bit of Chicago's finest culinary fare) from the busy week, we walked away with five key takeaways.

Brian McNally, PhD

Rare Disease Drug Development & Commercialization Learnings, Opportunities & Debates at World Orphan Drug Congress USA 2022

July 21, 2022 • The Kx team attended the World Orphan Drug Congress (WODC) in Boston, MA last week and came away energized from three days of sharing ideas, inspirational stories, and panel discussions.

Jenna Riffell, PhD and Brett Larson

Q&A with Kx: Spotlight on AACC 2022

July 6, 2022 • Before they head off to the Windy City for this year’s AACC Annual Scientific Meeting & Clinical Lab Expo, we asked Bob Serrano and Brian McNally for their insights on what they hope to learn, see, and are excited to discover at this year’s conference.

Bob Serrano and Brian McNally, PhD

Cell and Gene Therapy: The Next Frontier in Healthcare

June 5, 2022 • Cell and Gene Therapy (CGT) is one of the most promising new frontiers in advanced therapies with the potential for transformational disease-modifying outcomes. We analyze the state of the Cell & Gene Therapy pipeline and technologies driving growth.

Sean Vander Linde and 2 others

Strategizing for Your First Drug Launch

June 3, 2022 • Strategizing for your First Drug Launch: Supporting late-stage, pre-revenue pharmaceutical companies who are planning to directly commercialize their first product capitalize on these competitive advantages.

Chris Waybill

Digital Priorities of the C-Suite

March 28, 2022 • Learn how digital health companies enable health system digital transformation while remaining competitive against Big Tech

Rachael England

Home Dialysis: Unlocking New Opportunities in an Evolving Landscape

February 3, 2022 •

Read The 2020 Hot Indications List

Explore our thought leadership

The use of AI in imaging for Alzheimer’s Disease

Blogs and publications by sector

The use of AI in imaging for Alzheimer’s Disease

OSET 2024: The All-in-One Ortho Industry Meeting

Blood Biomarkers in Alzheimer’s Disease

Health Equity: The Kx Research Approach and Case Study

Evolving Considerations for Segmenting Aesthetic Practices

Alzheimer’s Disease Therapeutics and Diagnostics – Parallel Advancements for Patient Care

Women’s Health: The Opportunity in Gynecology and Beyond

For Patient Engagement solutions looking for an exit, 2023 could be their year

5 Misconceptions for MedTech Market Access Strategy

Using the Patient Journey to Understand Health Equity Challenges

Key Insights & Takeaways: American Association for Clinical Chemistry Annual Scientific Meeting & Clinical Lab Expo

Rare Disease Drug Development & Commercialization Learnings, Opportunities & Debates at World Orphan Drug Congress USA 2022

Q&A with Kx: Spotlight on AACC 2022

Cell and Gene Therapy: The Next Frontier in Healthcare

Strategizing for Your First Drug Launch

Digital Priorities of the C-Suite

Home Dialysis: Unlocking New Opportunities in an Evolving Landscape

Hot Indications List 2021: Hot MOAs

Key Considerations for Rare Disease Due Diligence

Six Considerations to Evolve Your Capital Equipment Pricing Strategy

Using Your Product Launch Forecast as a Strategic Tool

How Understanding Cognitive Bias Can Drive Patient Volumes

Kx’s Four-Step Customer Segmentation Process

Hot Indications List 2020 – Neurology

Hot Indications List 2020

Why Your Orphan Drug Needs A Global Market Access Strategy

How Medical Practices Can Keep Patients Safe: COVID-19 Best Strategies

How Does COVID-19 Change Clinical Pipeline Prioritization?

Elective Procedures After COVID-19: How To Support Rebounding Demand

Should You Do Market Research During COVID-19?

Adapting In COVID-19: A Product Forecasting Framework

3 Questions To Ask For Launch Planning During COVID-19

How Is COVID-19 Impacting Procedure Volume?

Hot Indications List 2019

Rare Diseases – Patient Advocacy

Rare Diseases – Stakeholder Education

Rare Diseases – Market Access

Developing a Winning Outpatient Strategy

Hot Indications List 2018 – Oncology

Hot Indications List 2018

Hot Indications List 2017 – Oncology

Hot Indications List 2017

Delivering Precision Medicine

2016 Hot Indications Deep Dive – Oncology

2016 Hot Indications Deep Dive – Immunology

Hot Indications List 2016

Hot Indications List 2015

Taking a Fresh Look at Co-Pay Assistance Programs

Explore our thought
leadership

Blogs and publications
by sector